Published in Neurology on April 01, 1997
Sleep, Awake & Move - Part I (SA&M-I) | NCT02723396
Prospective assessment of subjective sleep benefit in Parkinson's disease. BMC Neurol (2015) 0.84
Nocturnal sleep enhances working memory training in Parkinson's disease but not Lewy body dementia. Brain (2012) 0.81
Quantitative Motor Performance and Sleep Benefit in Parkinson Disease. Sleep (2015) 0.81
'Sleep benefit' in Parkinson's disease. Neurology (1998) 0.81
A grounded theory study on the influence of sleep on Parkinson's symptoms. BMC Res Notes (2016) 0.75
Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology (1981) 3.47
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology (1997) 2.85
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol (1996) 2.22
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol Pharmacol (1976) 1.93
Human amnion as an adjunct in wound healing. Lancet (1980) 1.92
Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology (2002) 1.90
Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol (2000) 1.80
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. Am J Hum Genet (1991) 1.77
Synaptic biochemistry of amino acids. Fed Proc (1973) 1.74
Associations between chronic disease, age and physical and mental health status. Chronic Dis Can (2009) 1.71
Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature (1976) 1.71
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology (2006) 1.69
Isolation and some properties of macrophage alpha-actinin: evidence that it is not an actin gelling protein. Biochemistry (1984) 1.61
Use of cytochalasin B to distinguish between early and late events in neutrophil activation. Biochim Biophys Acta (1980) 1.56
Rat mast cells permeabilized with ATP secrete histamine in response to calcium ions buffered in the micromolar range. J Physiol (1981) 1.52
Treatment of chronic ulceration of the legs with human amnion. Lancet (1980) 1.51
Stimulus-secretion coupling in rabbit neutrophils is not mediated by phosphatidylinositol breakdown. Nature (1980) 1.47
Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta (1997) 1.44
The dependence on Ca2+ of phosphatidylinositol breakdown and enzyme secretion in rabbit neutrophils stimulated by formylmethionyl-leucylphenylalanine or ionomycin. Biochem J (1981) 1.41
Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf (2011) 1.39
Inhibition of release of dopamine- -hydroxylase and norepinephrine from sympathetic nerves by colchicine, vinblastine, or cytochalasin-B (hypogastric nerve stimulation-exocytosis-microtubules-microfilaments-guinea pig). Proc Natl Acad Sci U S A (1972) 1.36
Health Heritage© a web-based tool for the collection and assessment of family health history: initial user experience and analytic validity. Public Health Genomics (2010) 1.31
Ionomycin stimulates mast cell histamine secretion by forming a lipid-soluble calcium complex. Nature (1980) 1.31
Neurotransmitter receptors in the brain: biochemical identification. Annu Rev Physiol (1976) 1.30
Enhanced release of dopamine -hydroxylase and norepinephrine from sympathetic nerves by dibutyryl cyclic adenosine 3', 5'-monophosphate and theophylline. Mol Pharmacol (1973) 1.27
Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology (2001) 1.25
On the mechanism of release of norepinephrine from sympathetic nerves induced by depolarizing agents and sympathomimetic drugs. Mol Pharmacol (1975) 1.23
The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta (1999) 1.23
Agonists vs levodopa in PD: the thrilla of whitha. Neurology (2003) 1.21
f-MetLeuPhe-induced phosphatidylinositol turnover in rabbit neutrophils is dependent on extracellular calcium. FEBS Lett (1980) 1.21
Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol (2000) 1.20
Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology (1998) 1.19
The effect of Parkinson's disease on interference control during action selection. Neuropsychologia (2008) 1.19
An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev (1999) 1.17
From noli-me-tangere to rodent ulcer: the recognition of basal cell carcinoma. Br J Plast Surg (1974) 1.14
Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 1.14
Development of striatal dopaminergic function. I. Pre- and postnatal development of mRNAs and binding sites for striatal D1 (D1a) and D2 (D2a) receptors. Brain Res Dev Brain Res (1996) 1.12
Elevated plasma dopamine- -hydroxylase activity in autosomal dominant torsion dystonia. N Engl J Med (1973) 1.10
Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol (1998) 1.09
A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial. Osteoporos Int (2008) 1.09
The impacts of distance to hospital on families with a child with a chronic condition. Soc Sci Med (2001) 1.08
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology (1997) 1.08
Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem (2001) 1.06
The effect of speed-accuracy strategy on response interference control in Parkinson's disease. Neuropsychologia (2009) 1.04
Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol (1998) 1.04
Parents' perceptions of chronic illness trajectories. Can J Nurs Res (2000) 1.03
Evidence-based pressure-ulcer practice: the Ottawa model of research use. Can J Nurs Res (1999) 1.02
Regulation of dopamine beta-hydroxylase in rat adrenal glands. J Biol Chem (1975) 1.01
Segregation analysis of Parkinson disease revealing evidence for a major causative gene. Am J Med Genet (2002) 1.01
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01
Leg ulcer care: nursing attitudes and knowledge. Can Nurse (2001) 1.01
Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem (1998) 1.01
Metabolic effects of unilateral lesion of the substantia nigra. J Neurosci (1981) 1.01
Clinical practice guidelines: necessary but not sufficient for evidence-based patient education and counseling. Patient Educ Couns (2001) 1.00
Inhibitory effects of natural flavonoids on secretion from mast cells and neutrophils. Arzneimittelforschung (1981) 1.00
Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology (1990) 0.99
Loss of cell surface microvilli on rat basophilic leukaemia cells precedes secretion and can be mimicked using the calmodulin antagonist trifluoperazine. Inflamm Res (1997) 0.98
Freeze-fracture studies of chemotactic peptide-induced exocytosis in neutrophils: evidence for two patterns of secretory granule fusion. J Ultrastruct Res (1983) 0.98
Sir William Fergusson, Bart, 1808-1877. Ann R Coll Surg Engl (1977) 0.98
Degranulation of individual mast cells in response to Ca2+ and guanine nucleotides: an all-or-none event. J Cell Biol (1993) 0.97
Specific glycine--accumulating synaptosomes in the spinal cord of rats. Proc Natl Acad Sci U S A (1972) 0.97
Neurochemical correlates of synaptically active amino acids. Life Sci (1974) 0.97
Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration (1996) 0.97
Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease. J Neurochem (2000) 0.96
Characterization and time course of MPP+ -induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res (1999) 0.96
Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord (1994) 0.96
Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem (2000) 0.96
Visualization of cyclosporin A and Ca2+-sensitive cyclical mitochondrial depolarizations in cell culture. Biochim Biophys Acta (1999) 0.96
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol (2001) 0.95
Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol (1998) 0.95
Stereospecific binding of D-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors. Brain Res (1975) 0.95
Angiotensin II binding to mammalian brain membranes. J Biol Chem (1976) 0.95
Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res (1991) 0.95
Postnatal development of D1 dopamine receptors in the medial prefrontal cortex, striatum and nucleus accumbens of normal and neonatal 6-hydroxydopamine treated rats: a quantitative autoradiographic analysis. Brain Res Dev Brain Res (1991) 0.95
The long-term results of the use of human amnion in the treatment of leg ulcers. Br J Plast Surg (1984) 0.94
The healing of chronic venous leg ulcers with prepared human amnion. Br J Plast Surg (1989) 0.94
The bacterial factors which stimulate neutrophils may be derived from procaryote signal peptides. FEBS Lett (1980) 0.94
Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Provincial Lung Disease Site Group of Cancer Care Ontario. Oncology (2000) 0.94
Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology (1997) 0.94
A68930: a potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol (1991) 0.94
Effects of colchicine and vinblastine on axonal transport and transmitter release in sympathetic nerves. Ann N Y Acad Sci (1975) 0.93
Plasma-membrane location of phosphatidylinositol hydrolysis in rabbit neutrophils stimulated with formylmethionyl-leucylphenylalanine. Biochem J (1982) 0.93
Amino acid neurotransmitter candidates: sodium-dependent high-affinity uptake by unique synaptosomal fractions. Science (1972) 0.92
Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Res (2001) 0.92
Plasma dopamine- -hydroxylase activity. Elevation in man during cold pressor test and exercise. Arch Neurol (1973) 0.91
Neurotensin, a central nervous system peptide: apparent receptor binding in brain membranes. Brain Res (1977) 0.91
Selective localization of striatal D1 receptors to striatonigral neurons. Brain Res (1990) 0.91
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord (1997) 0.90
A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study. Neurology (2003) 0.90
BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology (2005) 0.90
Quantitative film autoradiography of opiate agonist and antagonist binding in rat brain. J Pharmacol Exp Ther (1983) 0.90